The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Silent progression in disease activity–free relapsing multiple sclerosis
Open accessAbstract
Objective: Rates of worsening and evolution to secondary progressive multiple sclerosis (MS) may be substantially lower in actively treated patients compared to natural history studies from the pretreatment era. Nonetheless, in our recently reported prospective cohort, more than half of patients with relapsing MS accumulated significant new disability by the 10th year of follow‐up. Notably, “no evidence of disease activity” at 2 years did not predict long‐term stability. Here, we determined to what extent clinical relapses and radiographic evidence of disease activity contribute to long‐term disability accumulation. Methods: Disability progression was defined as an increase in Expanded Disability Status Scale (EDSS) of 1.5, 1.0, or 0.5 (or greater) from baseline EDSS = 0, 1.0–5.0, and 5.5 or higher, respectively, assessed from baseline to year 5 (±1 year) and sustained to year 10 (±1 year). Longitudinal analysis of relative brain volume loss used a linear mixed model with sex, age, disease duration, and HLA‐DRB1*15:01 as covariates. Results: Relapses were associated with a transient increase in disability over 1‐year intervals ( p = 0.012) but not with confirmed disability progression ( p = 0.551). Relative brain volume declined at a greater rate among individuals with disability progression compared to those who remained stable ( p < 0.05). Interpretation: Long‐term worsening is common in relapsing MS patients, is largely independent of relapse activity, and is associated with accelerated brain atrophy. We propose the term silent progression to describe the insidious disability that accrues in many patients who satisfy traditional criteria for relapsing–remitting MS. Ann Neurol 2019;85:653–666
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Zhang, Y., Brady, M., & Smith, S. (2001) · IEEE Transactions on Medical Imaging · doi:10.1109/42.906424 · Cited by 6,982
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Relapses and Progression of Disability in Multiple Sclerosis
Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432001 · Cited by 1,309
An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis
Schmidt, P., Gaser, C., Arsic, M., Buck, D., Förschler, A., Berthele, A., Hoshi, M., Ilg, R., Schmid, V. J., Zimmer, C., et al. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.032 · Cited by 1,223
Confavreux, C. (2003) · Brain · doi:10.1093/brain/awg081 · Cited by 996
Fisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., & Miller, D. H. (2008) · Brain · doi:10.1093/brain/awm329 · Cited by 897
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis
Brex, P. A., Ciccarelli, O., O'Riordan, J. I., Sailer, M., Thompson, A. J., & Miller, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011341 · Cited by 861
Frischer, J. M., Weigand, S. D., Guo, Y., Kale, N., Parisi, J. E., Pirko, I., Mandrekar, J., Bramow, S., Metz, I., Brück, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24497 · Cited by 728
The clinico-radiological paradox in multiple sclerosis revisited
Barkhof, F. (2002) · Current Opinion in Neurology · doi:10.1097/00019052-200206000-00003 · Cited by 726
Scalfari, A., Neuhaus, A., Degenhardt, A., Rice, G. P., Muraro, P. A., Daumer, M., & Ebers, G. C. (2010) · Brain · doi:10.1093/brain/awq118 · Cited by 711
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.6.1419 · Cited by 602
Evidence for a two-stage disability progression in multiple sclerosis
Leray, E., Yaouanq, J., Le Page, E., Coustans, M., Laplaud, D., Oger, J., & Edan, G. (2010) · Brain · doi:10.1093/brain/awq076 · Cited by 596
Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up
Runmarker, B., & Andersen, O. (1993) · Brain · doi:10.1093/brain/116.1.117 · Cited by 568
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Kuhle, J., Kropshofer, H., Haering, D. A., Kundu, U., Meinert, R., Barro, C., Dahlke, F., Tomic, D., Leppert, D., & Kappos, L. (2019) · Neurology · doi:10.1212/wnl.0000000000007032 · Cited by 568
Gray matter atrophy is related to long‐term disability in multiple sclerosis
Fisniku, L. K., Chard, D. T., Jackson, J. S., Anderson, V. M., Altmann, D. R., Miszkiel, K. A., Thompson, A. J., & Miller, D. H. (2008) · Annals of Neurology · doi:10.1002/ana.21423 · Cited by 500
Kappos, L., Moeri, D., Radue, E. W., Schoetzau, A., Schweikert, K., Barkhof, F., Miller, D., Guttmann, C. R., Weiner, H. L., Gasperini, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03053-0 · Cited by 499
Association between pathological and MRI findings in multiple sclerosis
Filippi, M., Rocca, M. A., Barkhof, F., Brück, W., Chen, J. T., Comi, G., DeLuca, G., De Stefano, N., Erickson, B. J., Evangelou, N., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70003-0 · Cited by 486
Long‐term evolution of multiple sclerosis disability in the treatment era
University of California, S. F. M. T., Cree, B. A. C., Gourraud, P., Oksenberg, J. R., Bevan, C., Crabtree‐Hartman, E., Gelfand, J. M., Goodin, D. S., Graves, J., Green, A. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24747 · Cited by 440
Self-citationEffect of relapses on development of residual deficit in multiple sclerosis
Lublin, F. D., Baier, M., & Cutter, G. (2003) · Neurology · doi:10.1212/01.wnl.0000096175.39831.21 · Cited by 421
Defining secondary progressive multiple sclerosis
Lorscheider, J., Buzzard, K., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., Trojano, M., Izquierdo, G., Girard, M., Duquette, P., et al. (2016) · Brain · doi:10.1093/brain/aww173 · Cited by 415
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
De Stefano, N., Giorgio, A., Battaglini, M., Rovaris, M., Sormani, M. P., Barkhof, F., Korteweg, T., Enzinger, C., Fazekas, F., Calabrese, M., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e24136 · Cited by 321
Kappos, L., De Stefano, N., Freedman, M. S., Cree, B. A., Radue, E.-W., Sprenger, T., Sormani, M. P., Smith, T., Häring, D. A., Piani Meier, D., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515616701 · Cited by 289
Self-citationSodium channels contribute to microglia/macrophage activation and function in EAE and MS
Craner, M. J., Damarjian, T. G., Liu, S., Hains, B. C., Lo, A. C., Black, J. A., Newcombe, J., Cuzner, M. L., & Waxman, S. G. (2005) · Glia · doi:10.1002/glia.20112 · Cited by 249
Optimized Brain Extraction for Pathological Brains (optiBET)
Lutkenhoff, E. S., Rosenberg, M., Chiang, J., Zhang, K., Pickard, J. D., Owen, A. M., & Monti, M. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115551 · Cited by 226
Impact of multiple sclerosis relapses on progression diminishes with time
Tremlett, H., Yousefi, M., Devonshire, V., Rieckmann, P., & Zhao, Y. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c1e44f · Cited by 221
Eriksson, M., Andersen, O., & Runmarker, B. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms914oa · Cited by 221
MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS)
Barkhof, F. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500415 · Cited by 215
Ford, C., Goodman, A., Johnson, K., Kachuck, N., Lindsey, J., Lisak, R., Luzzio, C., Myers, L., Panitch, H., Preiningerova, J., et al. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458509358088 · Cited by 207
Randomized study combining interferon and glatiramer acetate in multiple sclerosis
Lublin, F. D., Cofield, S. S., Cutter, G. R., Conwit, R., Narayana, P. A., Nelson, F., Salter, A. R., Gustafson, T., Wolinsky, J. S., & for the CombiRx Investigators (2013) · Annals of Neurology · doi:10.1002/ana.23863 · Cited by 203
Spinal cord gray matter atrophy correlates with multiple sclerosis disability
Schlaeger, R., Papinutto, N., Panara, V., Bevan, C., Lobach, I. V., Bucci, M., Caverzasi, E., Gelfand, J. M., Green, A. J., Jordan, K. M., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24241 · Cited by 196
Self-citationPredictors of long‐term disability accrual in relapse‐onset multiple sclerosis
Jokubaitis, V. G., Spelman, T., Kalincik, T., Lorscheider, J., Havrdova, E., Horakova, D., Duquette, P., Girard, M., Prat, A., Izquierdo, G., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24682 · Cited by 191
Gray and white matter volume changes in early RRMS: A 2-year longitudinal study
Tiberio, M., Chard, D. T., Altmann, D. R., Davies, G., Griffin, C. M., Rashid, W., Sastre-Garriga, J., Thompson, A. J., & Miller, D. H. (2005) · Neurology · doi:10.1212/01.wnl.0000154526.22878.30 · Cited by 168
Kappos, L., Butzkueven, H., Wiendl, H., Spelman, T., Pellegrini, F., Chen, Y., Dong, Q., Koendgen, H., Belachew, S. M., Trojano, M., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517709619 · Cited by 161
Genetic basis for clinical expression in multiple sclerosis
The Multiple Sclerosis Genetics Group, Barcellos, L. F., Oksenberg, J. R., Green, A. J., Bucher, P., Rimmler, J. B., Schmidt, S., Garcia, M., Lincoln, R., Pericak‐Vance, M. A., et al. (2002) · Brain · doi:10.1093/brain/awf009 · Cited by 157
Self-citationMRI evidence for multiple sclerosis as a diffuse disease of the central nervous system
Filippi, M., & Rocca, M. A. (2005) · Journal of Neurology · doi:10.1007/s00415-005-5004-5 · Cited by 145
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
Kappos, L., Edan, G., Freedman, M. S., Montalbán, X., Hartung, H., Hemmer, B., Fox, E., Barkhof, F., Schippling, S., Schulze, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003078 · Cited by 137
The Pathologic Substrate of Magnetic Resonance Alterations in Multiple Sclerosis
Lassmann, H. (2008) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2008.06.005 · Cited by 106
Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis
Isobe, N., Keshavan, A., Gourraud, P., Zhu, A. H., Datta, E., Schlaeger, R., Caillier, S. J., Santaniello, A., Lizée, A., Himmelstein, D. S., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0980 · Cited by 106
Self-citationKinkel, R. P., Dontchev, M., Kollman, C., Skaramagas, T. T., O'Connor, P. W., & Simon, J. H. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.1426 · Cited by 97
Goodin, D. S., Traboulsee, A. L., Knappertz, V. A., Reder, A. T., Li, D., Langdon, D. W., Wolf, C., Beckmann, K., Konieczny, A., Ebers, G. C., et al. (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301178 · Cited by 94
Self-citationFactors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
Kappos, L., Kühle, J., Multanen, J., Kremenchutzky, M., di Cantogno, E. V., Cornelisse, P., Lehr, L., Casset‐Semanaz, F., Issard, D., & Uitdehaag, B. M. J. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-310024 · Cited by 83
Bermel, R. A., Weinstock‐Guttman, B., BOURDETTE, D. N., Foulds, P., You, X., & Rudick, R. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458509360549 · Cited by 79
Mindcontrol: A web application for brain segmentation quality control
Keshavan, A., Datta, E., McDonough, I. M., Madan, C. R., Jordan, K., & Henry, R. G. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.03.055 · Cited by 66
Self-citationKühle, J., Hardmeier, M., Disanto, G., Gugleta, K., Ecsedi, M., Lienert, C., Amato, M. P., Baum, K., Buttmann, M., Bayas, A., et al. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515594440 · Cited by 32
pRNFL as a marker of disability worsening in the medium/long term in patients with MS
Cordano, C., Nourbakhsh, B., Devereux, M., Damotte, V., Bennett, D. J., Hauser, S. L., Cree, B., Gelfand, J. M., & Green, A. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000533 · Cited by 29
Self-citationBove, R. M., Chitnis, T., Cree, B., Tintoré, M., Naegelin, Y., Uitdehaag, B. M. J., Kappos, L., Khoury, S. J., Montalbán, X., Hauser, S. L., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517726657 · Cited by 24
Self-citationScott, T. F. M. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.02.011 · Cited by 9
Cited by
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
Self-citationMultiple sclerosis progression: time for a new mechanism-driven framework
Kuhlmann, T., Moccia, M., Coetzee, T., Cohen, J. A., Correale, J., Graves, J., Marrie, R. A., Montalban, X., Yong, V. W., Thompson, A. J., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00289-7 · Cited by 667
Self-citationKappos, L., Wolinsky, J. S., Giovannoni, G., Arnold, D. L., Wang, Q., Bernasconi, C., Model, F., Koendgen, H., Manfrini, M., Belachew, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1568 · Cited by 658
Self-citationJakimovski, D., Bittner, S., Zivadinov, R., Morrow, S. A., Benedict, R. H., Zipp, F., & Weinstock-Guttman, B. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01473-3 · Cited by 597
How patients with multiple sclerosis acquire disability
Lublin, F. D., Häring, D. A., Ganjgahi, H., Ocampo, A., Hatami, F., Čuklina, J., Aarden, P., Dahlke, F., Arnold, D. L., Wiendl, H., et al. (2022) · Brain · doi:10.1093/brain/awac016 · Cited by 549
“It may also be the case that 17 the loss of function over time is so gradual in some patients as to be unnoticed by the patient or 18 physician.(9) However, in contrast to the results previously reported from the EPIC study,(9) most (~90%) of 19 the 24,469 patients diagnosed with RRMS in our dataset did not experience…”
Metadata
- Authors
- University of California, S. F. M. T., Cree, B. A. C., Hollenbach, J. A., Bove, R., Kirkish, G., Sacco, S., Caverzasi, E., Bischof, A., Gundel, T., Zhu, A. H., Papinutto, N., Stern, W. A., Bevan, C., Romeo, A., Goodin, D. S., Gelfand, J. M., Graves, J., Green, A. J., Wilson, M. R., Zamvil, S. S., Zhao, C., Gomez, R., Ragan, N. R., Rush, G. Q., Barba, P., Santaniello, A., Baranzini, S. E., Oksenberg, J. R., Henry, R. G., & Hauser, S. L.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2019-03-30
- Volume
- 85
- Issue
- 5
- Pages
- 653-666
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2922528121
- Cited by
- 465
- References
- 49
- FWCI
- 30.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.